…ve included Cerexa (NLV-I, exited in sale to Forest Labs, 5.4x multiple), Stromedix (NLV-I, exited in sale to Biogen Idec, 1.8x multiple plus milestones), Chimerix (NLV-IL, IPO - April, 2013, NASDAQ: CMRxX), and Auxilium (Sprout IX, NASDAQ:...
Leadership: NLV_ are leaders in biopharmaceutical investing across all stages and transaction
IMAGES-007-HOUSE_OVERSIGHT_024045.txt
p.1
View source release ↗